5AM Ventures Sells Additional 75,840 Shares, Total Disposition Reaches $140K
SKYE is trading near its 52-week low of $0.276 (1.8% above the low) on elevated volume (3.4× avg).
Summary
5AM Ventures sold an additional 75,840 shares of Skye Bioscience on August 19-20, bringing its total three-day disposition to 375,840 shares for $140,313.
Key Events · Ownership and Investor Activity · SKYE
-
5AM Ventures Sells Additional Shares
Sold 75,840 shares on August 19-20 at $0.32-$0.35, bringing the three-day total to 375,840 shares for $140,313.
-
Total Disposition Exceeds Prior Disclosure
The Schedule 13D/A on August 18 disclosed only 300,000 shares sold; this Form 4 adds 75,840 more shares, a 25% increase in the total sold.
-
Sales Amid Reverse Merger and Delisting
The sales occur days after the Redx Pharma reverse merger announcement and a Nasdaq delisting notice for failing to meet minimum equity requirements.
-
Post-Transaction Holdings
5AM Ventures retains 7,914,126 shares after the sales, representing a significant but reduced stake.
Analysis · SKYE · Life Sciences
5AM Ventures, a 10% owner, sold an additional 75,840 shares on August 19-20 at $0.32-$0.35, bringing the three-day total to 375,840 shares for $140,313. This follows the 300,000 shares sold on August 18 disclosed in a Schedule 13D/A. The sales come amid a pending reverse merger with Redx Pharma and a Nasdaq delisting notice, suggesting the venture fund is reducing exposure ahead of the deal's completion.
How filings like this one have moved
In the 30 days to Aug 23, 2026, 29.5% of the 2875 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.02%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SKYE was trading at $0.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.9M. The 52-week trading range was $0.28 to $4.99. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.